Bethesda, MD (December 28, 2016) NCI Press Release: In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects 1 in 3,000 people. […]

Baltimore, MD (January 3, 2017)  Ashley Cannon, Ph.D., M.S., has been named the 2016 winner of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored by the Neurofibromatosis Therapeutic Acceleration Program at The Johns Hopkins University. The program works to create a community of expert clinician-scientists and grooms them to be […]

Baltimore, MD (October 1, 2014)  Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced that they have been selected as an Innovator Presenter at the 6th Annual Partnering for Cures meeting to be held in New York, NY, on November 16 – 18, 2014. This meeting is convened by FasterCures, a centre of the Milken Institute, which […]

Baltimore, MD (June 9, 2014)  Two early career physician-scientists, Peter de Blank and Matthew R. Steensma, have been named inaugural winners of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored by the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at The Johns Hopkins University. The program will create a community of expert […]

Baltimore, MD (March 15, 2013) Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced a request for proposals (RFP) for the development of Patient Reported Outcome (PRO) measures that can be used to support clinical development of therapies against plexiform neurofibromas (pNFs), one of the most common tumors seen in individuals with neurofibromatosis type 1 (NF1). PROs […]

Baltimore, MD (January 15, 2013) Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced the launch of an idea challenge for the development of biomarkers for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (pNF). Individuals with pNF can have multiple tumors that vary greatly in terms of how they progress. PNFs can grow to substantial volume over time, […]

Baltimore, MD (October 1, 2012) Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced a request for proposals (RFP) for the development of novel cell culture models for neurofibromatosis type 1 (NF1)-associated [...]

Baltimore, MD (September 22, 2012) Neurofibromatosis Therapeutic Acceleration Program (NTAP) held its inaugural Plexiform Neurofibroma Scientific Summit on September 20-22, 2012. Held at Nemacolin Woodlands Resort, the summit focused on [...]

Baltimore, MD (June 8, 2012) Today, the Neurofibromatosis Therapeutic Acceleration Program (NTAP) announced the launch of its operations, dedicated to improving treatment options for individuals with plexiform neurofibromas (pNFs). NTAP [...]